Anti-viral properties of interferon beta treatment in patients with multiple sclerosis

Abstract

Viral infections are potentially associated with the etiology and pathogenesis of multiple sclerosis (MS). It has been speculated that the treatment efficacy of interferon beta (IFN beta) in MS may relate to its anti-viral properties. The study was undertaken to evaluate the in vivo anti-viral effects of IFN beta-1a in patients with MS. Human herpesvirus-6 (HHV-6) was studied as an example for being a latent neurotropic virus. IFN beta used at concentrations of approximately 0.5 mg/ml was shown to significantly reduce in vitro HHV-6 replication in a susceptible T-cell line. Sera derived from 23 MS patients treated with IFN beta-1a were examined for serum cell-free DNA of HHV-6 as an indicator for viral replication and the reactivity of IgM antibodies to a recombinant HHV-6 virion protein containing a known immunoreactive region. The results were compared with those of control sera obtained from untreated MS (n=29) and healthy individuals (n=21). The findings indicated that IFN beta treatment significantly reduced HHV-6 replication as evident by decreased cell-free DNA in treated MS specimens. The results correlated with decreased IgM reactivity to the HHV-6 antigen in treated MS patients compared to untreated controls, suggesting reduced exposure to HHV-6. The findings were confirmed in paired sera obtained from seven MS patients before and after the treatment. The study provides new evidence indicating that IFN beta has potent in vivo anti-viral effects that may contribute to the treatment efficacy in MS.

Keywords

human herpesvirus-6 interferon beta multiple sclerosis

Get full access to this article

View all access options for this article.

References

Johnson RT. The virology of demyelinating diseases . Neurology 1994; 36(Suppl): S54-S60 .

Hunter SF , Hafler DA.

Ubiquitous pathogens. Links between infection and autoimmunity in MS?

Neurology 2000; 55: 164-165 .

Wandinger KP , et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS . Neurology 2000; 55: 178-184 .

Kennedy PGE , Steiner J. On the possible viral aetiology of multiple sclerosis . Q J Med 1994; 87: 523-528 .

Dalgleish AG. Viruses and multiple sclerosis . Acta Neurol Scand 1997; 95: 8-15 .

Yoshikawa T , Asano Y. Central nervous system complications in human herpesvirus-6 infection . Brain Dev 2000; 22: 307-314 .

Monteyne P , Bureau JF , Brahic M. Viruses and multiple sclerosis . Curr Opin Neurol 1998; 11: 287-291 .

Challoner PB , et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis . Proc Natl Acad Sci USA 1995; 92: 7440-7444 .

Kimberlin DW , Whitley RJ. Human herpesvirus-6: neurologic implications of a newly-described viral pathogen . J Neurovirol 1998; 4: 474-485 .

10.

Carrigan DR , Harrington D , Knox KK. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis . Neurology 1996; 47: 145-148 .

11.

Wucherpfennig KW , Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein . Cell 1995; 80: 695-705 .

12.

Hafler D. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis . J Clin Invest 1999; 104: 527-529 .

13.

Steinman L , Oldstone MBA.

More mayhem from molecular mimics. Antibodies against human herpesvirus-6 have been found in patients with multiple sclerosis. Could this be another sighting in the hunt for the viral trigger of the disease?

Nat Med 1997; 3: 1321-1322 .

14.

Lycke J , et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study . J Neurol 1996; 243: 214-224 .

15.

The IFNb Multiple Sclerosis Study Group . Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial . Neurology 1993; 43: 655-661 .

16.

Jacobs LD , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

17.

Bogdan C. The function of type I interferons in antimicrobial immunity . Curr Opin Immunol 2000; 12: 419-424 .

18.

Soldan SS , et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA . Nat Med 1997; 3: 1394-1397 .

19.

Poser CM , et al. New Diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

20.

Lublin FD , Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology 1996; 46: 907-911 .

21.

Pellett PE , et al. A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope . Virology 1993; 195: 521-531 .

22.

Khan O , Dhib-Jalbut S. Serum interferon B-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients . Neurology 1998; 51: 735-742 .

23.

Santoro F , et al. CD46 is a cellular receptor for human herpesvirus 6 . Cell 1999; 99: 817-827 .

24.

Rudick RA , et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis . Ann Neurol 1996; 40: 618-627 .

25.

Rudick RA , et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis . Neurol 1998; 50: 1294-1300 .

26.

Kozovska ME , et al. Interferon beta induces T-helper 2 immune deviation in MS . Neurology 1999; 53: 1692-1697 .

27.

Zang YCQ , et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS . Neurology 2000; 55: 397-404 .

28.

Leppert D , et al. Interferon beta 1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol 1996; 40: 846-852 .